Results 31 to 40 of about 214,611 (264)

Mechanisms of resistance to lapatinib in HER2 positive breast cancer [PDF]

, 2012
Lapatinib is a tyrosine kinase inhibitor of HER2 which blocks downstream signaling pathways in HER2 positive breast cancer cell lines, tumor xenografts and HER2 positive breast cancer patients.
McDermott, Martina
core   +1 more source

Therapeutic targeting of Integrin v 6 in breast cancer [PDF]

, 2014
BACKGROUND: Integrin ?v?6 promotes migration, invasion, and survival of cancer cells; however, the relevance and role of ?v?6 has yet to be elucidated in breast cancer.METHODS: Protein expression of integrin subunit beta6 (?6) was measured in breast ...
Thomas, GJ, Louise Jones, J., Eccles, D, Hart, I. R. (Ian R.), Kendrew, Jane, Chou, Patrick, Gillett, C., Jordan, L, Violette, S., Brentnall, A., Duffy, S.W., Warwick, J., Thomas, Gareth J., Saha, A, Hart, I.R., Bowen, R, Barry, S.T., Green, Andrew R, Gillett, Cheryl, Vallath, S, Bowen, R., Haider, Syed, Barry, Simon T, Moore, K.M., Hart, Ian R., Barry, Simon T., Gabe, R., Haider, S., Chelala, C, Jones, J.L., Thomas, Gareth J, Chelala, C., Eccles, Diana, Ellis, Ian O, Kendrew, J., Green, Andrew R., Weinreb, PH, Jones, JL, Chou, P, Vallath, S., Marshall, John F., Jordan, L., Brouilette, Kellie, Kendrew, J, Duffy, Stephen W, Ellis, I.O., Quinlan, P., Quinlan, P, Gabe, R, Haider, S, Moore, Kate M, Jordan, Lee, Hart, Ian R, Marshall, J.F., Brentnall, Adam, Moore, KM, Jones, J. Louise, Barry, ST, Gillett, C, Warwick, J, Thompson, Alastair M, Weinreb, Paul H, Vallath, Sabari, Chou, P., Green, AR, Thompson, A.M., Thompson, AM, Saha, Antonio, Violette, Sheila, Tapper, W.J., Hart, IR, Ellis, IO, Jones, J Louise, Tapper, William J., Brentnall, A, Weinreb, P.H., Brouilette, K., Tapper, Will, Gabe, Rhian, Thompson, Alastair M., Saha, A., Eccles, D., Violette, Shelia, Tapper, William J, Marshall, JF, Thomas, G J., Weinreb, Paul H., Duffy, Stephen W., Moore, Kate M., Brouilette, K, Green, A.R., Quinlan, Phillip, Duffy, SW, Ellis, Ian, Warwick, Jane, Marshall, John F, Bowen, Rebecca, Chelala, Claude, Tapper, WJ, Violette, S, Ellis, Ian O.   +100 more
core   +1 more source

The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab

Biomolecules, 2019
G309 or S310 mutations on the HER2 extracellular domain II induce receptor activation. Clinically, S310F is most frequent among HER2 extracellular domain mutations and patients with the S310F mutation without HER2 amplification responded to trastuzumab ...
Jung Won Shin, Soohyun Kim, Suji Ha, Byungsan Choi, Seongyeong Kim, Seock-Ah Im, Tae-Young Yoon, Junho Chung   +7 more
doaj   +1 more source

Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression [PDF]

, 2023
Background: Breast cancer (BC) expressing low levels of human epidermal growth factor receptor 2 (HER2 Low) is an emerging category that needs further refining. This study aims to provide a comprehensive clinico-pathological and molecular profile of HER2
Andrew R. Green, Atallah, Nehal M., Nigel P. Mongan, Haque, Maria, Rutland, Catrin S., Michael S. Toss, Cinzia Allegrucci, Mansour Alsaleem, Allegrucci, Cinzia, Ibrahim, Asmaa, Toss, Michael S., Rakha, Emad, Makhlouf, Shorouk, Shorouk Makhlouf, Maria Haque, Asmaa Ibrahim, Alsaleem, Mansour, Mongan, Nigel P., Cecily Quinn, Green, Andrew R., Quinn, Cecily, Nehal M. Atallah, Catrin S. Rutland, Emad Rakha   +23 more
core   +1 more source

Epidemiological and pathological characteristics of postsurgical cases of invasive breast cancer among ethnicities of Iran in 2018: A single center cross-sectional study [PDF]

Archive of Oncology, 2020
Background: Present study aimed to investigate immunohistochemical parameters in post-surgical cases of invasive breast cancer. Methods: In this single center cross-sectional study we investigated ethnicity, familial history, type of cancer, stage of ...
Sayad Soheila, Yasin Ahmadi Seyyed Amir, Nekouian Reza, Panahi Mahshid, Anbari Khatereh   +4 more
doaj  

Salvage Mastectomy Is not the Treatment of Choice for Aggressive Subtypes of Ipsilateral Breast Cancer Recurrence: A Single-Institution Retrospective Study

European Journal of Breast Health, 2022
Objective:Patients with triple-negative (TN) or human epidermal growth factor 2 (HER2)-enriched ipsilateral breast cancer recurrence (IBCR) seem to be excluded from a second breast-conserving surgery (BCS) under the assumption that salvage mastectomy ...
Damiano Gentile, Andrea Sagona, Ruggero Spoto, Davide Franceschini, Stefano Vaccari, Valeriano Vinci, Ersilia Biondi, Lorenzo Scardina, Corrado Tinterri   +8 more
doaj   +1 more source

Targeting HER2 in breast cancer: new drugs and paradigms on the horizon

Exploration of Targeted Anti-tumor Therapy, 2021
About 15–20% of all breast cancers (BCs) are defined human epidermal growth factor receptor 2 (HER2)-positive, based on the overexpression of HER2 protein and/or amplification of ERBB2 gene.
Paolo Tarantino, Stefania Morganti, Giuseppe Curigliano   +2 more
doaj   +1 more source

Clinical characteristics and survival analysis of rare mutations in locally advanced or metastatic lung adenocarcinoma

陆军军医大学学报, 2022
Objective To analyze the efficacy and safety of different treatments in advanced lung adenocarcinoma patients with v-raf murine sarcoma viral oncogene homolog B1(BRAF) BRAF V600E mutation, human epidermal growth factor receptor 2 (HER2) mutation ...
LIN Qingyue, QU Jingjing, ZHOU Jianying
doaj   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Retrospective Analysis of Transcriptomic Differences between Triple-Negative Breast Cancer (TNBC) and non-TNBC

European Journal of Biology
Objective: Triple-negative breast cancer (TNBC), which has no expression of estrogen receptor, progesterone receptor and HER2, is an aggressive subgroup.
Çağlar Berkel
doaj   +1 more source